Dr Sue Xiang, Senior Research Fellow

  • Honorary Research Associate, Ovarian Cancer Biomarkers
  • Senior Project Manager, Epworth Research Institute, Epworth HealthCare
  • Sessional Teaching, Department of Immunology and Pathology, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University
  •    sue.xiang@monash.edu

Dr Sue Xiang has a long-standing career in the area of research and development, particularly in the field of vaccines and cancer immunology. Dr Xiang’s research focus has been primarily on the development of novel nanovaccines (using engineered nanoparticles) and immunotherapies against cancers, in particular, ovarian cancer. She established an ovarian cancer mouse model in Monash Laboratories, providing tools for the researchers in this area. She is also one of the primary inventors for a new immune-dominant target as ovarian cancer immunotherapy. Dr Xiang is passionate about developing a novel immunotherapeutic approach for the treatment of ovarian cancer as well as identifying markers for monitoring disease progression. Working closely with Dr Andrew Stephens in the Ovarian Cancer Biomarkers Laboratory at the Hudson Institute of Medical Research, she is investigating the biological importance of sperm protein in ovarian cancer and its use as a target for early diagnosis and treatment of ovarian cancer.

Selected publications

  • Xiang SD, Selomulya C, Hardy C, Fuchsberger M, Karlson T and Plebanski M (2016) Nanoparticles and vaccine delivery and efficacy. In Handbook of Immunological Properties of Engineered Nanomaterials 2nd Edn. Dobrovolskaia MA and McNeil SE, eds. Singapore: World Scientific Publishing Company Pte Ltd. 3:101-129.

  • Xiang SD, Gao Q, Wilson K, Heyerick A, Plebanski M (2015) A nanoparticle based Sp17 peptide vaccine exposes new immuno-dominant and species cross-reactive B cell epitopes. Vaccines 3: 875-893.

  • Xiang SD, Gao Q, Wilson K, Heyerick A, Plebanski M (2015) Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine. Vaccine, 33:5950-5959.

  • Nguyen TH, Tan AC, Xiang SD, Goubier A, Harland KL, Clemens EB, Plebankski M, Kedzierska K (2017) Understanding CD8+ T cell responses towards native and alternate HLA-A*02:01-restricted WT1 epitope. Clin Transl Immunology 6:e134.

  • Wilson, K, Xiang SD and Plebanski M (2016) Inflammatory/Non-inflammatory adjuvants and nanotechnology – The secret to vaccine design. In: Micro and Nanotechnology in Vaccine Development. Skwarczynski M and Toth I, eds. Philadelphia, PA: Elsevier. 99-127.

  • Tsirikis P, Xiang SD, Selomulya C, Plebanski M (2017) Design of nanoparticle structures for cancer immunotherapy. In: Nanostructures for Cancer Therapy 1st Edn. Grumezescu A and Ficai A, eds. Philadelphia, PA, Elsevier. 1:307-328.

  • Xiang SD, Kong YY, Hanley J, Fuchsberger M, Crimeen-Irwin B, Plebanski M (2015) Nanoparticles modify dendritic cell homeostasis and induce non-specific effects on immunity to malaria. Trans R Soc Trop Med Hyg 109:70-76.

  • Xiang SD, Wilson K, Day S, Fuchsberger M, Plebanski M (2013) Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers. Methods 60:232-241.

  • Park A, Govindaraj C, Xiang SD, Halo J, Quinn MA, Scalzo-Inguanti K, Plebanski M (2012) Substantially modified ratios of effector to regulatory T cells during treatment in ovarian cancer patients return to pre-chemotherapy levels at completion: Implications for immunotherapy. Cancer 4:581-600.

  • Xiang SD, Selomulya C, Ho J, Apostolopoulos V, Plebanski M (2010) Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:205-218.

  • Xiang SD, Scalzo-Inguanti K, Minigo G, Park A, Hardy CL, Plebanski M (2008) Promising particle-based vaccines in cancer therapy. Expert Rev Vaccines 7:1103-1119.

  • Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, Plebanski M (2006) Editorial review: Pathogen recognition and development of particulate vaccines: does size matter? Methods 40:1-9.